Sermorelin

Product Details

Sermorelin (GRF 1-29) — Research Grade Peptide, ≥98% Purity (HPLC)

GHRH analog. Growth hormone secretagogue. Lyophilized powder. Lot-specific COA included.

Sermorelin is a synthetic 29-amino-acid peptide corresponding to the amino-terminal segment of endogenous human growth hormone-releasing hormone (GHRH). It binds to GHRH receptors on anterior pituitary somatotrophs and activates a Gs protein-coupled cAMP signaling cascade that drives GH synthesis and release. This pathway preserves natural GH pulsatility and somatostatin feedback, creating a more physiologic release pattern than direct GH administration.

The compound’s clinical history is the most extensive in the GHRH analog class. In a randomized, double-masked, placebo-controlled trial of 89 participants aged 60 to 85, six months of sermorelin treatment produced a 33.8% increase in IGF-1 levels, correlating with improved cognitive performance in novel problem-solving, psychomotor processing speed, and working memory. In pediatric growth hormone deficiency, once-daily subcutaneous sermorelin at 30 μg/kg bodyweight was effective in promoting growth in some prepubertal children with idiopathic GH deficiency.

Adult body composition data is more limited. A 1997 trial found no significant change in total body fat or BMI, and body-weight change with sermorelin alone, without lifestyle changes, stays under 1% over six months. Men gained approximately 1.26 kg of lean mass, while total body fat, BMI, and bone mineral density did not change significantly in either sex.

Supplied as a sterile-filtered, lyophilized powder for in vitro and preclinical research applications. Each lot is independently verified for purity and identity and ships with a Certificate of Analysis.

Specifications

Note: Sermorelin is supplied in both free base and acetate salt forms. The acetate form has a molecular formula of C₁₄₉H₂₄₆N₄₄O₄₂S·C₂H₄O₂ and a molecular weight of approximately 3417.94 g/mol. Some suppliers list a CAS number of 516482-86-3 for a related form. Verify the exact form, molecular weight, and purity against the Certificate of Analysis supplied with your lot.

Research applications

Sermorelin is used in laboratory settings to investigate:

• GHRH receptor signaling — activation of Gs protein-coupled cAMP signaling in anterior pituitary somatotrophs, driving GH synthesis and release

• GH/IGF-1 axis research — dose-dependent increases in IGF-1 levels, with a 33.8% increase observed in a 6-month trial of 89 adults aged 60–85

• Cognitive function research — improvements in novel problem-solving, psychomotor processing speed, and working memory in healthy older adults, with exploratory findings suggesting benefit in adults with MCI

• Pediatric growth hormone deficiency research — once-daily subcutaneous administration at 30 μg/kg bodyweight effective in promoting growth in some prepubertal children with idiopathic GH deficiency

• Diagnostic research — GHRH-arginine stimulation testing as a reliable alternative for diagnosing adult GH deficiency

• Body composition research — modest increases in lean mass without significant changes in total body fat or BMI in adult trials

• Analytical method development — LC-MS/MS quantification and reference standard preparation for GHRH analog analysis in biological matrices

Handling and storage

Reconstitute under aseptic conditions using sterile water or an appropriate aqueous buffer. Sermorelin is soluble in water. Aliquot immediately after reconstitution to avoid repeated freeze-thaw cycles. Lyophilized powder is stable for up to 2 years at −20 °C under sealed, desiccated, light-protected conditions. Reconstituted solutions should be stored at 2–8 °C and used within 14–21 days. Do not freeze reconstituted solution.

For laboratory use by qualified personnel only.